Get started
Author

Alessia Romagnoli

Observed names: A Romagnoli, A. Romagnoli
ORCID: 0000-0001-8705-5837
Observed ORCID: 0000-0001-8705-5837
OpenAlex ID: A5085476863
Healthcare Systems and Artificial Intelligence: Focus on Challenges and the International Regulatory Framework
2024 · Alessia Romagnoli, Francesco Ferrara, et al. · Pharmaceutical Research · 28
Adherence and persistence analysis after three years in real-life of inhalation therapies used in the treatment of COPD
2020 · Alessia Romagnoli, Fiorenzo Santoleri, et al. · Current Medical Research and Opinion · 12
Long-acting Injectable vs. Oral Antipsychotics: Adherence, Persistence and Switching over three Years of Real-life Analysis
2020 · Alessia Romagnoli, Fiorenzo Santoleri, et al. · Current Clinical Pharmacology · 12
Time to treatment discontinuation in first-line non-small cell lung carcinoma: an overview
2023 · Ruggero Lasala, Andrea Zovi, et al. · Current Medical Research and Opinion · 9
Medication adherence reporting in pivotal clinical trials: overview of oral oncological drugs
2022 · Ruggero Lasala, Fiorenzo Santoleri, et al. · European Journal of Hospital Pharmacy · 9
PDF
A multicentre study with real-world data of the use of palbociclib in the treatment of breast cancer: Treatment duration correlates with dose reductions
2022 · Felice Musicco, Ruggero Lasala, et al. · Journal of Oncology Pharmacy Practice · 8
The impact of COVID-19 on chronic therapies: the Pescara (ASL) local health authority experience in Italy
2021 · Alessia Romagnoli, Fiorenzo Santoleri, et al. · Current Medical Research and Opinion · 8
Drug utilisation pattern over 3 years in the real‐world treatment of type II diabetes
2021 · Alessia Romagnoli, Fiorenzo Santoleri, et al. · International Journal of Clinical Practice · 8
PDF
Adalimumab and etanercept adherence, persistence and switch in the treatment of psoriatic arthritis: 10-year real-life analysis
2019 · Fiorenzo Santoleri, Alessia Romagnoli, et al. · Expert Opinion on Drug Safety · 8
Therapeutic innovation and digital therapies in the world: Comparison between the American and European regulatory framework, with focus on Italy
2023 · Alessia Romagnoli, Andrea Zovi, et al. · Journal of Interprofessional Education & Practice · 7
Adherence and persistence in the use of statins and ezetimibe over 8 years in a real-life study
2021 · Fiorenzo Santoleri, Alessia Romagnoli, et al. · Current Medical Research and Opinion · 7
Cancer drugs for solid tumors approved by the EMA since 2014: an overview of pivotal clinical trials
2020 · Ruggero Lasala, Andrea Logreco, et al. · European Journal of Clinical Pharmacology · 7
Randomized clinical trials and real life studies: Comparison of baseline characteristics of patients in oral target therapies for renal cell carcinoma
2021 · Ruggero Lasala, Fiorenzo Santoleri, et al. · Journal of Oncology Pharmacy Practice · 6
Antidepressant deprescribing: State of the art and recommendations—A literature overview
2024 · Alessia Romagnoli, Andrea Zovi, et al. · European Journal of Clinical Pharmacology · 5
Adherence and persistence analysis in patients treated with double antiplatelet therapy (DAPT) at two years in real life
2021 · Alessia Romagnoli, Fiorenzo Santoleri, et al. · Patient Education and Counseling · 5
The Development of Digital Therapies as a New Therapeutic Option to Treat Diseases: Focus on the International Regulatory Framework
2023 · Alessia Romagnoli, Filomena Valentino, et al. · Journal of Pharmaceutical Innovation · 4
Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe
2019 · Ruggero Lasala, Fiorenzo Santoleri, et al. · European Journal of Clinical Pharmacology · 3
Statin deprescribing: a comprehensive review and development of a clinical algorithm for optimal patient management
2026 · Tiziano Lupi, Fabio Esposito, et al. · Internal Medicine Journal · 2
Telepharmacy and telemedicine: New challenges in the international regulatory framework of the healthcare landscape
2025 · A. Romagnoli, F.Ferrara, et al. · Ethics Medicine and Public Health · 2
Real-life adherence in capecitabine therapy using two analysis methods and persistence after 6 months of treatment
2020 · Fiorenzo Santoleri, Alessia Romagnoli, et al. · Journal of Oncology Pharmacy Practice · 2
From data to evidence: the evolving role of observational studies and target trial emulation in regulatory decision-making
2025 · Maurizio Polignano, Ruggero Lasala, et al. · AboutOpen · 1
PDF
Adherence, persistence and switching rates of apixaban, dabigatran and rivaroxaban in non-valvular atrial fibrillation: a multicentre real-life analysis at 3 years
2022 · Alessia Romagnoli, Fiorenzo Santoleri, et al. · European Journal of Hospital Pharmacy · 1
PDF
Available information about paediatric use of onco-haematological drugs authorized by EMA since 2016
2021 · Ruggero Lasala, Fiorenzo Santoleri, et al. · Journal of Oncology Pharmacy Practice · 1
5PSQ-214 ‘Unit dose’: clinical risk management of COVID-19 patients treated with hydroxychloroquine
2021 · S Corridoni, P Sorice, et al. · European Journal of Hospital Pharmacy · 1
PDF
Use and Costs of Originator and Biosimilar Erythropoiesis-Stimulating Agents in the Treatment of Chemotherapy-Induced Anemia: Real-World Evidence from an Italian Hospital
2018 · Fiorenzo Santoleri, Alessia Romagnoli, et al. · Future Oncology · 1
Works count: 33
Citation count: 153
H-index: 8
I10-index: 3
Year
Topic
Type